Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Thoughts following a conference call with TH Management

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jul 20, 2022 2:14pm

90 Views

Post# 34837854

RE:RE:Thoughts following a conference call with TH Management

This is the problem with JMF
He says below that we have proof of concept and when challenged he backtracks the next day and again today

jfm1330 wrote: Thanks for this information, it's the main reason I still follow this board. That being said, and it will not surprise you, I disagree at this point with your frustration. You tell us they follow a plan to replicate the IMMU huge success story. In my view, if it's the case they walk a fine line. I mean by that, that you want to go public the next time with a news spectacular enough that it will propel the SP much higher. What would be the point to show your incredible hand too early with no meaningful impact. Le the predators out there sleep. We know we have the proof of concept and it's the most important thing for now. This time, it will not take 15 months for them to come with good news. If what they have is what we think it is, for all the frustration we got waiting for results, this company would have pulled a masterful move by buying Katana. The fact that their model is Immunomedics says a lot about what their ambitions are.

SPCEO1 wrote: To be able to buy THTX on a market cap of $200 million (less than three times sales) and with this kind of cancer data giving us lots of reasons to expect more positive data in the future – well that is just nuts. But we cannot be the only ones who knows what is going on – they have to get the word out and I am not at all convinced yet they will do that in a timely fashion.